% | $
Quotes you view appear here for quick access.

OncoSec Medical Incorporated Message Board

  • greatdayforinvestments greatdayforinvestments Feb 26, 2014 2:01 PM Flag

    "And if it works against other solid tumors, it could be a multibillion-dollar product."


    The key to Northwest's survival has been delivering strong trial results in a tiny cadre of patients for its brain-cancer drug, called DCVax-L. A similar drug called DCVax-Direct has begun testing for a wide array of solid tumors that cannot be removed by surgery, including cancers of the colon, pancreas, breast and melanoma.

    They are among an emerging new crop of drugs that coax the body's own immune system into tracking down and killing cancer cells. More specifically they harness dendritic cells, master cells of the immune system that give marching orders to its soldiers, including t-cells and b-cells, which make antibodies.

    Northwest Biotherapeutics' entry into the high-stakes field follows two high-profile disappointments of dendritic cell-based therapies from ImmunoCellular Therapeutics Ltd and Dendreon Corp .

    Powers, chief executive since 2011, is making the case to investors that the future of its drugs looks far different.

    "If (DCVax-L) has a positive result, it could be the new standard of care for brain cancer and have potential for hundreds of millions of dollars in sales for newly diagnosed patients," said Carol Werther, a biotech analyst for Summer Street Research. "And if it works against other solid tumors, it could be a multibillion-dollar product."

    Some highlight from the NWBO article out today! Immunotherapy is the future!

    Sentiment: Strong Buy

    This topic is deleted.
    SortNewest  |  Oldest  |  Most Replied Expand all replies
0.268-0.009(-3.42%)Apr 24 3:56 PMEDT